Navigation Links
Squamous Cell Cancer Responds to SPDT Therapy
Date:1/5/2012

ork quickly and have no side effects," Jimenez explained. "We treat the physical, emotional and spiritual aspects of cancer, and our success rates rival anything conventional medicine has to offer."

One of those aggressive therapies is SonoPhoto Dynamic Therapy (SPDT).  Dr. Jimenez is considered the world expert in this treatment method.   Patients are given a natural chlorophyll powder under the tongue, which is quickly absorbed by all the cells.  Within 24 hours, normal cells wash it back out, but it remains in the cancer cells.  Then sound and light frequencies are  pulsed through the body.  When sound and light hit chlorophyll, it causes photosynthesis, which is a chemical reaction that explodes free radical oxygen right into the cancer cells and kills them.  Tumors shrink up to 30% in just the first 14 days of treatment.

"I did my research," Miller explained.   "In the US, anything other than standard of care – surgery, chemotherapy and radiation – is considered 'alternative'.  Even chiropractic, acupuncture and massage are considered alternative.  What the word really means is that if it doesn't include drugs or surgery the FDA doesn't consider it effective.  Yet dozens of countries with higher success rates than the US use these treatments as front line therapy. Twenty years ago, doctors were run out of the country for using Vitamin C infusions.  Now they are done by medical doctors all over the country.  Hopefully someday we'll learn that drugs aren't always the answer, and these more natural therapies will become the norm.  Our medical establishment just hasn't caught up yet."

Miller's protocol included local and whole body hyperthermia, SonoPhoto Dynamic Therapy, IVs, vaccines, detoxification, nutrition, immune support, biological dentistry and lifestyle counseling.  "They gave me tools to work with," he said.   "They taught me ab
'/>"/>

SOURCE TMD Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Top-Line Results Announced of Pivotal Phase 3 Motesanib Trial in Advanced Non-Squamous Non-Small Cell Lung Cancer Patients
2. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
3. BioStorage Technologies Partners with Susan G. Komen for the Cure Tissue Bank at IU Simon Cancer Center to Raise Money and Awareness for Breast Cancer Research
4. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
5. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
6. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
7. Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH)
8. Agendia to Present Five Abstracts at 2011 San Antonio Breast Cancer Symposium
9. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
10. Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
11. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... ... orthopedic surgeon, Wade McKenna, DO, announced today that the use of sterile, dehydrated ... in complete healing of an otherwise non-healing surgical knee wound. , The case ...
(Date:8/27/2015)... 27, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") ... Biohaven Pharmaceutical Holding Company Limited (Biohaven), announced today ... study of BHV-0223, a glutamate modulating agent. Biohaven ... and recently obtained clearance from the U.S. Food ... testing. Portage holds 54% equity interest in Biohaven, ...
(Date:8/27/2015)... , August 27, 2015 GlassesOff (OTCBB: ... processing functions in the human vision system, announced today a ... point guard Chris Paul to develop a new ... want to improve their real-life on-court performance. Vision ... whether it is shooting a ball or blocking a pass. ...
(Date:8/26/2015)... ... August 26, 2015 , ... ... that a second US laboratory is to open in Manhattan, Kansas in early ... partnership and long-term growth of research and development through collaboration with researchers from ...
Breaking Biology Technology:Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3
... flowers: in the nineties of the last century Norwegian ... in petunias inhibited its activity instead of reinforcing it ... was found that the mechanism is based on the ... the late nineties the Nobel prizewinners Andrew Fire and ...
... deal with the same problems, but they use different ... be difficult, if not impossible., A new $2.9 million ... National Science Foundation (NSF), will help bridge this problematic ... common problems a range of scientists face., The grant ...
... Quest Diagnostics,Incorporated (NYSE: DGX ), the nation,s leading ... is scheduled to speak,at the 2007 UBS Global Life ... 2007. The Quest Diagnostics presentation is scheduled to,begin at ... webcast live during the conference and will be,available to ...
Cached Biology Technology:Mechanism for the in-vivo transport of siRNA 2Mechanism for the in-vivo transport of siRNA 3CCMR gets $2.9M for training grad students in nanoscale science 2Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference 2
(Date:8/5/2015)... -- According to a new market research ... Vertical (BFSI, Airport, IT & Telecom, Utilities, Education, Defense ... 2020", published by MarketsandMarkets, defines and segments the Physical ... The global PIAM Market is estimated to grow from ... at a CAGR of 14.9 % from 2014 to ...
(Date:8/4/2015)... 2015 Research ... the addition of the "Digital Forensics ... Sub-Segment (Computer Forensics, Network Forensics, Mobile Device ... Vertical and Region - Global Forecast to ... By Component (Hardware, Software, and Service), ...
(Date:7/31/2015)... , Kina, 31. juli 2015 Den ... bliver afholdt af BGI fra den 22. - 25. oktober ... Konferencen fejrer sin 10-års fødselsdag i år. Siden ... mest indflydelsesrige årlige møder på ,omik,-feltet, og er en ... ICG-10 fokuserer på nylige gennembrud og ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... hundreds, if not thousands, of suspected toxic substances every ... the brain, immune system, reproductive organs or hormones. Children ... requires product testing of most chemical compounds before they ... Riverside professor Carl Cranor argues in a new book, ...
... research effort designed to prevent the introduction of viruses to ... Chesapeake Bay watermen improve their bottom line by reducing the ... The findings, published in the journal Diseases of Aquatic ... in diseased and dying crabs likely occurs after the pre-molt ...
... scientists of the Technische Universitaet Muenchen (TUM) have been ... Prof. Stephan A. Sieber for the development of drugs ... million to study interactions between cellular components; 1.6 million ... a basic theory on elementary particles; Prof. Daniel Cremers ...
Cached Biology News:Legally poisoned 2Blue crab research may help Chesapeake Bay watermen improve soft shell harvest 2Nearly 10 million euros ($13.6 million) in ERC grants for 6 Technische Universitaet Muenchen researchers 2Nearly 10 million euros ($13.6 million) in ERC grants for 6 Technische Universitaet Muenchen researchers 3Nearly 10 million euros ($13.6 million) in ERC grants for 6 Technische Universitaet Muenchen researchers 4Nearly 10 million euros ($13.6 million) in ERC grants for 6 Technische Universitaet Muenchen researchers 5Nearly 10 million euros ($13.6 million) in ERC grants for 6 Technische Universitaet Muenchen researchers 6
Anti-DAP-1, Rabbit Monoclonal Immunogen: KLH-conjugated synthetic peptide corresponding to the C-terminal region of human DAP-1. Molecular Weight: 11 kDa Quality Assurance: Routinely eval...
Mouse monoclonal [TONI-1] to Angiotensin II Type 1 Receptor (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 185 SwissProtID: P30556...
1/4" to 1/8" Adapter for Reflectance Probe Holder...
... (GLP-1), C-terminal reactive. Cross-reacts fully with ... reactivity with the unamidated forms GLP-1(7-37) ... such as hGLP-2, glucagon, hGIP and ... is identical in all mammalian species ...
Biology Products: